Business & Technology Briefs (06/2007)
Brief summaries of recent product and company developments in the device industry, including Aspect Medical's brain monitoring technology, Warburg's bid for Bausch & Lomb, and Frazier Healthcare Venture's investment in publicly-traded Endocare.
You may also be interested in...
A $10.9 billion bid by a consortium of private equity investors to buy Biomet raises questions about whether this is the first of many such deals or an outlier.
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.